相似文献
1
T cells and B cells in lupus nephritis.
Semin Nephrol. 2007 Jan;27(1):47-58. doi: 10.1016/j.semnephrol.2006.09.007.
2
Lupus nephritis. How latest insights into its pathogenesis promote novel therapies.
Curr Opin Rheumatol. 2012 Sep;24(5):457-65. doi: 10.1097/BOR.0b013e328354c877.
3
Lupus nephritis: update on pathogenesis and disease mechanisms.
Semin Nephrol. 1999 Mar;19(2):173-81.
4
B cells and autoantibodies in the pathogenesis of lupus nephritis.
Immunol Res. 1998;17(1-2):123-32. doi: 10.1007/BF02786437.
5
Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells.
J Immunol. 1999 May 15;162(10):5775-83.
6
Nucleosomes contribute to increase mesangial cell chemokine expression during the development of lupus nephritis.
Cytokine. 2013 May;62(2):244-52. doi: 10.1016/j.cyto.2013.03.016. Epub 2013 Apr 4.
7
Experimental models of lupus nephritis.
Contrib Nephrol. 2011;169:183-197. doi: 10.1159/000319241. Epub 2011 Jan 20.
8
Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
J Immunol. 2012 Apr 15;188(8):3628-38. doi: 10.4049/jimmunol.1102859. Epub 2012 Mar 9.
9
Therapeutic potential of DCB-SLE1, an extract of a mixture of Chinese medicinal herbs, for severe lupus nephritis.
Am J Physiol Renal Physiol. 2011 Oct;301(4):F751-64. doi: 10.1152/ajprenal.00706.2010. Epub 2011 Jun 15.
10
Lupus nephritis: role of antinucleosome autoantibodies.
Semin Nephrol. 2011 Jul;31(4):376-89. doi: 10.1016/j.semnephrol.2011.06.009.
引用本文的文献
1
Anti-C1q Autoantibody-Binding Engineered scFv C1q-Mimicking Fragment Enhances Disease Progression in Lupus-Prone MRL/lpr Mice.
Int J Mol Sci. 2025 Jul 22;26(15):7048. doi: 10.3390/ijms26157048.
2
Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis.
Int J Mol Sci. 2024 Jun 3;25(11):6162. doi: 10.3390/ijms25116162.
3
Three Diseases Mediated by Different Immunopathologic Mechanisms-ANCA-Associated Vasculitis, Anti-Glomerular Basement Membrane Disease, and Immune Complex-Mediated Glomerulonephritis-A Common Clinical and Histopathologic Picture: Rapidly Progressive Crescentic Glomerulonephritis.
Biomedicines. 2023 Nov 6;11(11):2978. doi: 10.3390/biomedicines11112978.
4
SHP2: its association and roles in systemic lupus erythematosus.
Inflamm Res. 2023 Jul;72(7):1501-1512. doi: 10.1007/s00011-023-01760-w. Epub 2023 Jun 23.
5
ITGAM rs1143679 Variant in Systemic Lupus Erythematosus Is Associated with Increased Serum Calcification Propensity.
Genes (Basel). 2023 May 18;14(5):1105. doi: 10.3390/genes14051105.
6
Axl regulated survival/proliferation network and its therapeutic intervention in mouse models of glomerulonephritis.
Arthritis Res Ther. 2022 Dec 28;24(1):284. doi: 10.1186/s13075-022-02965-w.
7
Predicting diagnostic gene expression profiles associated with immune infiltration in patients with lupus nephritis.
Front Immunol. 2022 Dec 2;13:839197. doi: 10.3389/fimmu.2022.839197. eCollection 2022.
8
Inhibition of CEBPB Attenuates Lupus Nephritis via Regulating Pim-1 Signaling.
Mediators Inflamm. 2022 Sep 20;2022:2298865. doi: 10.1155/2022/2298865. eCollection 2022.
9
Clinical relevance of glomerular IgM deposition in patients with lupus nephritis.
BMC Immunol. 2021 Dec 7;22(1):75. doi: 10.1186/s12865-021-00467-z.
10
Urinary soluble alpha chain of the interleukin-2 receptor as a biomarker of active lupus nephritis in Egyptian children with juvenile systemic lupus erythematosus.
Arch Rheumatol. 2020 Jun 26;36(1):47-55. doi: 10.46497/ArchRheumatol.2021.8001. eCollection 2021 Mar.
本文引用的文献
1
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.
Nature. 2006 May 11;441(7090):235-8. doi: 10.1038/nature04753. Epub 2006 Apr 30.
2
Fcgamma receptors: old friends and new family members.
Immunity. 2006 Jan;24(1):19-28. doi: 10.1016/j.immuni.2005.11.010.
3
A case for regulatory B cells.
J Immunol. 2006 Jan 15;176(2):705-10. doi: 10.4049/jimmunol.176.2.705.
4
Facing the enigma of immunomodulatory effects of intravenous immunoglobulin.
Clin Rev Allergy Immunol. 2005 Dec;29(3):185-99. doi: 10.1385/CRIAI:29:3:185.
5
Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1).
J Immunol. 2005 Dec 1;175(11):7185-92. doi: 10.4049/jimmunol.175.11.7185.
6
Inducible co-stimulator null MRL-Faslpr mice: uncoupling of autoantibodies and T cell responses in lupus.
J Am Soc Nephrol. 2006 Jan;17(1):122-30. doi: 10.1681/ASN.2005080802. Epub 2005 Nov 16.
7
B cell abnormality and autoimmune disorders.
Autoimmunity. 2005 Aug;38(5):331-7. doi: 10.1080/08916930500123959.
8
A defect in deletion of nucleosome-specific autoimmune T cells in lupus-prone thymus: role of thymic dendritic cells.
J Immunol. 2005 Nov 1;175(9):5857-65. doi: 10.4049/jimmunol.175.9.5857.
9
Manipulation of immune regulation in systemic lupus erythematosus.
Autoimmun Rev. 2005 Nov;4(8):515-9. doi: 10.1016/j.autrev.2005.04.008.
10
Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus.
J Exp Med. 2005 Aug 1;202(3):341-4. doi: 10.1084/jem.20050221.
Zotero 插件